Abstract 363P
Background
Oral cancer is distressing cancer that affects physically and emotionally and is associated with an adverse impact on mental well-being and financial distress. Informal caregivers are a significant source of support to the patient during and after the treatment of cancer patients. Caregiving may become a burden leading to poor quality of life among caregivers. The study intends to evaluate the effect of a patient's financial distress and psychological well-being on the caregiver's health-related quality of life in early vs advanced oral cancer.
Methods
All oral cancer patients treated with curative intent at our institute from September 2019 to March 2022, with a minimum of 6 months follow-up and disease-free, were included in this study, along with the informal caregivers of the patients. Caretakers not suffering from chronically ill and incurable diseases are included in the study. Patients and caregivers were categorised into early-stage (Group A) and advanced-stage (Group B) based on the clinical staging of patients with oral cancer. The patient's financial distress was evaluated using the COST FACIT questionnaire, and Psychological well-being using DASS 21 questionnaire. The quality of life of the caregivers was evaluated using the WHOQOL BREF questionnaire.
Results
A total of 79 patients and their caregivers were included. The median age is 49 among patients and 38 among caregivers. Twenty-one were in Group A; the rest, fifty-eight, were in Group B. It was observed that the patient in group B has Significant financial distress (p<0.05). There was no difference in HRQOL among caregivers of both groups. There was no correlation between financial distress scores and the caregiver's QOL. There was no effect of the patient's psychological well-being on the QOL of caregivers in group A. However, patients with depression in group B had a significant impact on the caregivers' QOL in the psychological (p <0.05) and environmental domains (p <0.05).
Conclusions
The lack of psychological well-being of patients with advanced-stage cancer significantly influences informal caregivers' psychological and environmental quality of life domains.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract